Beam Therapeutics (BEAM)
Nasdaq Market Closed
Beam Therapeutics Inc. is a biotechnology company developing precision genetic medicines based on base editing, a gene-editing approach designed to make targeted single-letter changes in DNA without creating the double-strand breaks associated with some earlier editing methods. The company’s work is aimed at serious diseases where a durable or potentially lifelong treatment could alter the course of illness rather than manage symptoms over time.
Beam’s pipeline is centered on hematology, liver-mediated genetic diseases, and other programs that use its editing and delivery capabilities. BEAM-101 is one of its most closely watched candidates and is being developed for sickle cell disease through an ex vivo process that edits a patient’s hematopoietic stem cells before they are returned to the body. The goal is to increase fetal hemoglobin production and reduce the effects of the disease.
The company is also advancing in vivo editing, including BEAM-302, a liver-targeted program that uses lipid nanoparticles to deliver editing components for alpha-1 antitrypsin deficiency. This reflects Beam’s broader strategy of matching base editors with delivery technologies suited to different tissues and disease biology.
Beam operates as a clinical-stage company, so its value is closely tied to scientific execution, trial progress, regulatory outcomes, manufacturing capability, and funding needs. Its common stock gives investors exposure to the emerging field of next-generation gene editing, where the potential market is large but development timelines, safety considerations, and clinical uncertainty remain significant.
Last updated
- Market Cap
- 3.04B
- P/E
- —
- P/FCF
- —
- P/S
- 18.54
- Enterprise Value
- 2.85B
- Sector
- Health Care
- Industry
- Biological Products, Except Diagnostic Substances
- Address
- 26 LANDSDOWNE STREET, CAMBRIDGE, MA, 02139
Beam Therapeutics Presents Recently Reported Topline Clinical Data for BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) at the American Thoracic Society (ATS) 2026 International Conference
Beam Therapeutics Announces Compelling Updated Clinical Data from the Ongoing Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) to Support Advancement to Pivotal Development
Beam Therapeutics Announces $500 Million Strategic Financing Facility with Sixth Street
Beam Therapeutics to Host Investor Webcast for Fourth Quarter and Year-End 2025 Financial Results and New Liver-targeted Genetic Disease Program
Beam Therapeutics Reports Updated Data from BEACON Phase 1/2 Trial of ristoglogene autogetemcel (risto-cel) Highlighting Durable, Differentiated Profile in Sickle Cell Disease (SCD) at American Society of Hematology (ASH) Annual Meeting
Beam Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)
Beam Therapeutics Announces Pricing of Underwritten Offering
Beam Therapeutics to Participate in Upcoming March 2025 Investor Conferences
Beam Therapeutics to Participate in Guggenheim SMID Cap Biotech Conference
Beam Therapeutics Presents New Non-human Primate (NHP) Data Demonstrating Proof-of-concept for ESCAPE, a Non-genotoxic, Antibody-based Conditioning Approach to Treating Sickle Cell Disease, at American Society of Hematology (ASH) Annual Meeting
Beam Therapeutics Announces New Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 in Sickle Cell Disease at American Society of Hematology (ASH) Annual Meeting
Beam Therapeutics Announces Transition of Chief Financial Officer - GlobeNewswire
Here's Why You Should Invest in Beam Therapeutics (BEAM) Now - Zacks Investment Research
Beam Therapeutics Announces First Patient Dosed in the Phase 1/2 Study of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD)
Beam Therapeutics Reports Data Highlighting Optimized Manufacturing Process for BEAM-101, an Investigational Base Editing Therapeutic for Sickle Cell Disease
Why Is Beam Therapeutics (BEAM) Up 10.1% Since Last Earnings Report?
Beam Therapeutics to Participate in Jefferies Global Healthcare Conference
Beam Therapeutics (BEAM) Q1 Loss Narrows, Revenues Miss
Beam Therapeutics to Participate in RBC Capital Markets 2024 Global Healthcare Conference
Beam Therapeutics Reports Pipeline Updates and First Quarter 2024 Financial Results
- Market Cap
Market cap is the total value of a company's shares, calculated by multiplying the stock price by the number of shares outstanding.
- 3.04B
- Enterprise Value
Enterprise value is the total value of a company, including its market cap, debt, and cash.
- 2.85B
- P/E
P/E ratio compares a company's share price to its earnings per share.
- —
- P/B
P/B ratio compares a company's share price to its book value per share.
- 2.61
- P/S
P/S ratio compares a company's share price to its revenue per share.
- 18.54
- EV / EBITDA
EV/EBITDA measures a company's value compared to its earnings before interest, taxes, depreciation, and amortization.
- -8.17
- EV / Sales
EV/Sales measures a company's value compared to its total revenue.
- 17.39
- EPS
- -0.63
- Dividend Yield
Dividend yield shows how much a company pays in dividends each year compared to its share price.
- 0%
- P/FCF
Price-to-free-cash-flow ratio compares a company's share price to the cash it generates after expenses and investments.
- —
- P/CF
P/CF ratio compares a company's share price to the cash flow it generates from its operations.
- —
- Free Cash Flow
Free cash flow is the cash a company has left after covering operating costs and capital expenses.
- -383.84M
- ROE
ROE measures how effectively a company uses shareholders' equity to generate profit.
- -5.59%
- ROA
ROA measures how effectively a company uses its assets to generate profit.
- -4.39%
- Debt / Equity
Debt-to-equity ratio compares a company's total debt to its shareholders' equity.
- 0.09
- Current Ratio
Current ratio measures a company's ability to pay short-term debts using its short-term assets.
- 16.99
- Quick Ratio
Quick ratio measures a company's ability to pay short-term debts using cash and other easily available assets.
- 16.99
- Cash
Cash ratio measures a company's ability to cover short-term debts using only cash and cash equivalents.
- 3.87
- Avg Volume
Average volume shows the average number of shares traded over the last 30 trading days, helping indicate liquidity.
- 2.09M
- Fundamentals Snapshot Price
Fundamentals snapshot price is the stock price used when calculating the company's financial ratios and metrics.
- 29.55
Income Statement
| Line Item | 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 | 2025 Q1 |
|---|---|---|---|---|---|
| Revenue | 31.74M | 114.11M | 9.7M | 8.47M | 7.47M |
| Gross profit | 31.74M | 114.11M | 9.7M | 8.47M | 7.47M |
| Operating income | -107.22M | -17.45M | -126.81M | -120.15M | -119.29M |
| EBITDA | -101.61M | -11.78M | -121.25M | -114.61M | -113.76M |
| Net income | -94.32M | 244.3M | -112.73M | -102.29M | -108.33M |
| Basic EPS | -0.91 | 2.51 | -1.1 | -1 | -1.23 |
| Diluted EPS | -0.91 | 2.51 | -1.1 | -1 | -1.23 |
Balance Sheet
| Line Item | 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 | 2025 Q1 |
|---|---|---|---|---|---|
| Total assets | 1.48B | 1.48B | 1.31B | 1.39B | 1.47B |
| Total liabilities | 316.36M | 242.82M | 345.08M | 344.34M | 343.78M |
| Total equity | 1.16B | 1.24B | 966M | 1.05B | 1.12B |
| Cash & equivalents | 288.29M | 294.94M | 267.96M | 282.13M | 527.91M |
| Current assets | 1.27B | 1.27B | 1.1B | 1.18B | 1.25B |
| Current liabilities | 74.57M | 96.94M | 182.56M | 174.13M | 141.55M |
Cash Flow
| Line Item | 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 | 2025 Q1 |
|---|---|---|---|---|---|
| Operating cash flow | -128.51M | -83.29M | -81.48M | -76.45M | -103.88M |
| Investing cash flow | 25.27M | 108.41M | 65.66M | -170.41M | -125.09M |
| Financing cash flow | 96.61M | 1.89M | 1.68M | 1.11M | 473.38M |
| Change in cash | -6.64M | 27M | -14.15M | -245.75M | 244.41M |
| Kind | Filing | Date | Link |
|---|---|---|---|
| edgar index | 8-K — Beam Therapeutics Inc. | View Filing | |
| edgar index | 10-Q — Beam Therapeutics Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | SCHEDULE 13G — Beam Therapeutics Inc. | View Filing | |
| edgar index | DEF 14A — Beam Therapeutics Inc. | View Filing | |
| edgar index | DEFA14A — Beam Therapeutics Inc. | View Filing | |
| edgar index | ARS — Beam Therapeutics Inc. | View Filing | |
| edgar index | 144 — Beam Therapeutics Inc. | View Filing | |
| edgar index | 4 — Beam Therapeutics Inc. | View Filing | |
| edgar index | 4 — Beam Therapeutics Inc. | View Filing | |
| edgar index | 4 — Beam Therapeutics Inc. | View Filing | |
| edgar index | 4 — Beam Therapeutics Inc. | View Filing | |
| edgar index | 4 — Beam Therapeutics Inc. | View Filing | |
| edgar index | 4 — Beam Therapeutics Inc. | View Filing | |
| edgar index | 4 — Beam Therapeutics Inc. | View Filing | |
| edgar index | 4 — Beam Therapeutics Inc. | View Filing | |
| edgar index | 4 — Beam Therapeutics Inc. | View Filing | |
| edgar index | 4 — Beam Therapeutics Inc. | View Filing | |
| edgar index | 4 — Beam Therapeutics Inc. | View Filing | |
| form 4 | Form 4 — Ciaramella Giuseppe | View Filing | |
| form 4 | Form 4 — Bellon Christine | View Filing | |
| form 4 | Form 4 — Cavanagh Bethany J | View Filing | |
| form 4 | Form 4 — Simon Amy | View Filing | |
| form 4 | Form 4 — Evans John M. | View Filing | |
| form 4 | Form 4 — Evans John M. | View Filing | |
| form 4 | Form 4 — Evans John M. | View Filing | |
| form 4 | Form 4 — Evans John M. | View Filing | |
| form 4 | Form 4 — Evans John M. | View Filing | |
| form 4 | Form 4 — Evans John M. | View Filing | |
| form 4 | Form 4 — Ciaramella Giuseppe | View Filing | |
| form 4 | Form 4 — Emany Sravan Kumar | View Filing | |
| form 4 | Form 4 — Simon Amy | View Filing | |
| form 4 | Form 4 — Cavanagh Bethany J | View Filing | |
| form 4 | Form 4 — Bellon Christine | View Filing | |
| edgar index | 144 — Beam Therapeutics Inc. | View Filing | |
| form 4 | Form 4 — Evans John M. | View Filing | |
| form 4 | Form 4 — Evans John M. | View Filing | |
| form 4 | Form 4 — Evans John M. | View Filing | |
| form 4 | Form 4 — Evans John M. | View Filing | |
| edgar index | SCHEDULE 13G/A — Beam Therapeutics Inc. | View Filing | |
| edgar index | 8-K — Beam Therapeutics Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | 4 — Beam Therapeutics Inc. | View Filing | |
| edgar index | 8-K — Beam Therapeutics Inc. | View Filing | |
| edgar index | 10-K — Beam Therapeutics Inc. | View Filing | |
| edgar index | S-8 — Beam Therapeutics Inc. | View Filing | |
| edgar index | 144 — Beam Therapeutics Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| form 4 | Form 4 — Ciaramella Giuseppe | View Filing | |
| form 4 | Form 4 — Ciaramella Giuseppe | View Filing | |
| form 4 | Form 4 — Ciaramella Giuseppe | View Filing | |
| ten k section | 10-K — business | View Filing | |
| ten k section | 10-K — mda | View Filing | |
| ten k section | 10-K — risk_factors | View Filing | |
| edgar index | 8-K — Beam Therapeutics Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | SCHEDULE 13G — Beam Therapeutics Inc. | View Filing | |
| edgar index | SCHEDULE 13G/A — Beam Therapeutics Inc. | View Filing | |
| edgar index | SCHEDULE 13G/A — Beam Therapeutics Inc. | View Filing | |
| edgar index | 8-K — Beam Therapeutics Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | SCHEDULE 13G/A — Beam Therapeutics Inc. | View Filing | |
| edgar index | 4 — Beam Therapeutics Inc. | View Filing | |
| edgar index | 4 — Beam Therapeutics Inc. | View Filing | |
| edgar index | 4 — Beam Therapeutics Inc. | View Filing | |
| edgar index | 4 — Beam Therapeutics Inc. | View Filing | |
| edgar index | 4 — Beam Therapeutics Inc. | View Filing | |
| edgar index | 4 — Beam Therapeutics Inc. | View Filing | |
| form 4 | Form 4 — Simon Amy | View Filing | |
| form 4 | Form 4 — Evans John M. | View Filing | |
| form 4 | Form 4 — Bellon Christine | View Filing | |
| form 4 | Form 4 — Emany Sravan Kumar | View Filing | |
| form 4 | Form 4 — Cavanagh Bethany J | View Filing | |
| form 4 | Form 4 — Ciaramella Giuseppe | View Filing | |
| edgar index | 144 — Beam Therapeutics Inc. | View Filing |